Treatment of Refractory Peripheral T-cell Lymphoma with Denileukin Diftitox (ONTAK ® )

Abstract

Peripheral T-cell lymphomas (PTCLs) are an uncommon and heterogeneous group of well-differentiated, post-thymic T-cell malignancies that can present in the skin as cutaneous T-cell lymphomas. In general, their prognosis is poor, and specific therapy is not well defined. We report the successful treatment of a patient with relapsed, refractory PTCL who after failing 13 standard single and multiple chemotherapy regimens and experimental agents had a dramatic prolonged response to diftitoxin denileukin (ONTAK ® ). This fusion protein, composed of diphtheria toxin coupled to interleukin-2, is approved for cutaneous T-cell lymphomas, including mycosis fungoides, and should be considered for treatment of the rare subset of peripheral T-cell lymphomas.

• Cutaneous T-cell Lymphoma
• Serum Soluble Il-2 Receptor
• Denileukin Diftitox
• Dab-IL2
• Ontak ®
• Peripheral T-cell Lymphoma